Technical Analysis for ADAP - Adaptimmune Therapeutics plc

Grade Last Price % Change Price Change
C 1.47 -0.68% -0.01
ADAP closed down 0.68 percent on Monday, March 18, 2024, on 54 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Hammer Candlestick Bullish 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction -0.68%
Narrow Range Bar Range Contraction -0.68%
Inside Day Range Contraction -0.68%
Wide Bands Range Expansion -0.68%
Oversold Stochastic Weakness -0.68%
Fell Below 20 DMA Bearish 0.68%

   Recent Intraday Alerts

Alert Time
Up 2% about 12 hours ago
2x Volume Pace about 14 hours ago
1.5x Volume Pace about 14 hours ago
Down 5% about 14 hours ago
Rose Above Previous Day's High about 14 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Adaptimmune Therapeutics plc Description

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Acid Immunotherapy Cancer Treatment Cancer Immunotherapy Virotherapy Non Small Cell Lung Cancer Ovarian Cancer Melanoma Small Cell Lung Cancer Multiple Myeloma Sarcoma Peptides Hematological Malignancies Oncolytics Biotech Adoptive Cell Transfer Immunotherapy Products Tumors Of The Hematopoietic And Lymphoid Tissues Amino Acids Cancer Immunotherapy Product Synovial Sarcoma Breast And Lung Cancer Esophageal Cancer

Is ADAP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.05
52 Week Low 0.42
Average Volume 2,011,465
200-Day Moving Average 0.86
50-Day Moving Average 1.19
20-Day Moving Average 1.55
10-Day Moving Average 1.57
Average True Range 0.18
RSI (14) 51.92
ADX 39.55
+DI 29.78
-DI 19.99
Chandelier Exit (Long, 3 ATRs) 1.52
Chandelier Exit (Short, 3 ATRs) 1.71
Upper Bollinger Bands 1.79
Lower Bollinger Band 1.30
Percent B (%b) 0.35
BandWidth 31.63
MACD Line 0.09
MACD Signal Line 0.13
MACD Histogram -0.0407
Fundamentals Value
Market Cap 333.87 Million
Num Shares 227 Million
EPS -0.54
Price-to-Earnings (P/E) Ratio -2.72
Price-to-Sales 3.83
Price-to-Book 3.22
PEG Ratio 0.11
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.70
Resistance 3 (R3) 1.68 1.60 1.66
Resistance 2 (R2) 1.60 1.54 1.60 1.64
Resistance 1 (R1) 1.53 1.50 1.49 1.55 1.63
Pivot Point 1.45 1.45 1.43 1.45 1.45
Support 1 (S1) 1.38 1.39 1.34 1.40 1.31
Support 2 (S2) 1.30 1.35 1.30 1.30
Support 3 (S3) 1.23 1.30 1.28
Support 4 (S4) 1.25